Compass Pathways' depression treatment meets main goal in late‑stage study
17/02/2026 11:37
Feb 17 (Reuters) - Drug developer Compass Pathways CMPS.O said on Tuesday its psilocybin-based depression therapy met the main goal in a late-stage study. (Reporting by Sahil Pandey in Bengaluru; Editing by Devika Syamnath) ((Sahil.Pandey@thomsonreuters.com;))
Recent news on COMPASS Pathways
See all newsCompass Pathways PLC reports results for the quarter ended September 30 - Earnings Summary
Corrected: Compass Pathways Q3 net loss narrows on lower R&D charges
Corrected: BRIEF-COMPASS Pathways Q3 EPS USD -0.31
Psychedelic drug developers fall after Usona submits depressive drug application
Compass Pathways PLC expected to post a loss of 45 cents a share - Earnings Preview